Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Accumulated Expenses (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Accumulated Expenses data on record, last reported at $351000.0 in Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 387.5% year-over-year to $351000.0; the TTM value through Sep 2025 reached $351000.0, up 387.5%, while the annual FY2024 figure was $52000.0, 42.22% down from the prior year.
  • Accumulated Expenses reached $351000.0 in Q3 2025 per CYCN's latest filing, up from $266000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $4.8 million in Q2 2022 and bottomed at $15000.0 in Q2 2024.
  • Average Accumulated Expenses over 5 years is $1.1 million, with a median of $351000.0 recorded in 2025.
  • Peak YoY movement for Accumulated Expenses: plummeted 96.24% in 2023, then surged 1673.33% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $1.4 million in 2021, then crashed by 86.41% to $186000.0 in 2022, then crashed by 51.61% to $90000.0 in 2023, then plummeted by 42.22% to $52000.0 in 2024, then surged by 575.0% to $351000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $351000.0 in Q3 2025, $266000.0 in Q2 2025, and $534000.0 in Q1 2025.